Disease response and pretreatment disease burden impact CAR T-cell expansion. In vivo CAR T-cell expansion (peak CAR T-cell VCN per milliliter) in peripheral blood was also higher in patients with disease response (responders), compared with nonresponders (P = .01) (A), and in patients with MRD, compared with morphologic pretreatment disease burden (P = .05) (B).